191 related articles for article (PubMed ID: 9528800)
1. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2.
Durick K; Gill GN; Taylor SS
Mol Cell Biol; 1998 Apr; 18(4):2298-308. PubMed ID: 9528800
[TBL] [Abstract][Full Text] [Related]
2. Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain.
Durick K; Wu RY; Gill GN; Taylor SS
J Biol Chem; 1996 May; 271(22):12691-4. PubMed ID: 8662982
[TBL] [Abstract][Full Text] [Related]
3. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
Mercalli E; Ghizzoni S; Arighi E; Alberti L; Sangregorio R; Radice MT; Gishizky ML; Pierotti MA; Borrello MG
Oncogene; 2001 Jun; 20(27):3475-85. PubMed ID: 11429694
[TBL] [Abstract][Full Text] [Related]
4. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
Besset V; Scott RP; Ibáñez CF
J Biol Chem; 2000 Dec; 275(50):39159-66. PubMed ID: 10995764
[TBL] [Abstract][Full Text] [Related]
5. Grb2 binding to the different isoforms of Ret tyrosine kinase.
Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
[TBL] [Abstract][Full Text] [Related]
6. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor.
Hayashi H; Ichihara M; Iwashita T; Murakami H; Shimono Y; Kawai K; Kurokawa K; Murakumo Y; Imai T; Funahashi H; Nakao A; Takahashi M
Oncogene; 2000 Sep; 19(39):4469-75. PubMed ID: 11002419
[TBL] [Abstract][Full Text] [Related]
7. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
Borrello MG; Alberti L; Arighi E; Bongarzone I; Battistini C; Bardelli A; Pasini B; Piutti C; Rizzetti MG; Mondellini P; Radice MT; Pierotti MA
Mol Cell Biol; 1996 May; 16(5):2151-63. PubMed ID: 8628282
[TBL] [Abstract][Full Text] [Related]
8. Novel recruitment of Shc, Grb2, and Sos by fibroblast growth factor receptor-1 in v-Src-transformed cells.
Curto M; Frankel P; Carrero A; Foster DA
Biochem Biophys Res Commun; 1998 Feb; 243(2):555-60. PubMed ID: 9480847
[TBL] [Abstract][Full Text] [Related]
9. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
[TBL] [Abstract][Full Text] [Related]
10. Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase.
Scott RP; Eketjäll S; Aineskog H; Ibáñez CF
J Biol Chem; 2005 Apr; 280(14):13442-9. PubMed ID: 15677445
[TBL] [Abstract][Full Text] [Related]
11. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
[TBL] [Abstract][Full Text] [Related]
12. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.
Knauf JA; Kuroda H; Basu S; Fagin JA
Oncogene; 2003 Jul; 22(28):4406-12. PubMed ID: 12853977
[TBL] [Abstract][Full Text] [Related]
13. The src homology 2 and phosphotyrosine binding domains of the ShcC adaptor protein function as inhibitors of mitogenic signaling by the epidermal growth factor receptor.
O'Bryan JP; Lambert QT; Der CJ
J Biol Chem; 1998 Aug; 273(32):20431-7. PubMed ID: 9685397
[TBL] [Abstract][Full Text] [Related]
14. Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells.
Sakaguchi K; Okabayashi Y; Kido Y; Kimura S; Matsumura Y; Inushima K; Kasuga M
Mol Endocrinol; 1998 Apr; 12(4):536-43. PubMed ID: 9544989
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins.
Borrello MG; Pelicci G; Arighi E; De Filippis L; Greco A; Bongarzone I; Rizzetti M; Pelicci PG; Pierotti MA
Oncogene; 1994 Jun; 9(6):1661-8. PubMed ID: 8183561
[TBL] [Abstract][Full Text] [Related]
16. Differential interaction of Enigma protein with the two RET isoforms.
Borrello MG; Mercalli E; Perego C; Degl'Innocenti D; Ghizzoni S; Arighi E; Eroini B; Rizzetti MG; Pierotti MA
Biochem Biophys Res Commun; 2002 Aug; 296(3):515-22. PubMed ID: 12176011
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon.
Piiper A; Elez R; You SJ; Kronenberger B; Loitsch S; Roche S; Zeuzem S
J Biol Chem; 2003 Feb; 278(9):7065-72. PubMed ID: 12496267
[TBL] [Abstract][Full Text] [Related]
18. The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.
Waterman H; Alroy I; Strano S; Seger R; Yarden Y
EMBO J; 1999 Jun; 18(12):3348-58. PubMed ID: 10369675
[TBL] [Abstract][Full Text] [Related]
19. Shc binding to nerve growth factor receptor is mediated by the phosphotyrosine interaction domain.
Dikic I; Batzer AG; Blaikie P; Obermeier A; Ullrich A; Schlessinger J; Margolis B
J Biol Chem; 1995 Jun; 270(25):15125-9. PubMed ID: 7541035
[TBL] [Abstract][Full Text] [Related]
20. Identification of Shc docking site on Ret tyrosine kinase.
Arighi E; Alberti L; Torriti F; Ghizzoni S; Rizzetti MG; Pelicci G; Pasini B; Bongarzone I; Piutti C; Pierotti MA; Borrello MG
Oncogene; 1997 Feb; 14(7):773-82. PubMed ID: 9047384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
